The Intermediate Mass Black Hole Candidate in the Center of NGC 404: New Evidence from Radio Continuum Observations

We present the results of deep, high-resolution, 5 GHz Expanded Very Large Array (EVLA) observations of the nearby, dwarf lenticular galaxy and intermediate mass black hole candidate (M ~4.5 x 10^5 M_sun), NGC 404. For the first time, radio emission at frequencies above 1.4 GHz has been detected in this galaxy. We found a modestly resolved source in the NGC 404 nucleus with a total radio luminosity of 7.6 +/- 0.7 x 10^17 W/Hz at 5 GHz and a spectral index from 5 to 7.45 GHz of alpha = -0.88 +/- 0.30. NGC 404 is only the third central intermediate mass black hole candidate detected in the radio regime with subarcsecond resolution. The position of the radio source is consistent with the optical center of the galaxy and the location of a known, hard X-ray point source (Lx ~1.2 x 10^37 erg/s). The faint radio and X-ray emission could conceivably be produced by an X-ray binary, star formation, a supernova remnant or a low-luminosity AGN powered by an intermediate mass black hole. In light of our new EVLA observations, we find that the most likely scenario is an accreting intermediate mass black hole, with other explanations incompatible with the observed X-ray and/or radio luminosities or statistically unlikely.Comment: Accepted for publication to Ap

A double-blind, randomized, comparative study of the use of a combination of uridine triphosphate trisodium, cytidine monophosphate disodium, and hydroxocobalamin, versus isolated treatment with hydroxocobalamin, in patients presenting with compressive neuralgias

CONTEXT: This paper reports on the results of treatment of compressive neuralgia using a combination of nucleotides (uridine triphosphate trisodium [UTP] and cytidine monophosphate disodium [CMP]) and vitamin B(12). OBJECTIVES: To assess the safety and efficacy of the combination of nucleotides (UTP and CMP) and vitamin B(12) in patients presenting with neuralgia arising from neural compression associated with degenerative orthopedic alterations and trauma, and to compare these effects with isolated administration of vitamin B(12). METHODS: A randomized, double-blind, controlled trial, consisting of a 30-day oral treatment period: Group A (n=200) receiving nucleotides + vitamin B(12,) and Group B (n=200) receiving vitamin B(12) alone. The primary study endpoint was the percentage of subjects presenting pain visual analog scale (VAS) scores ≤20 at end of study treatment period. Secondary study endpoints included the percentage of subjects presenting improvement ≥5 points on the patient functionality questionnaire (PFQ); percentage of subjects presenting pain reduction (reduction in VAS scores at study end in relation to pretreatment); and number of subjects presenting adverse events. RESULTS: The results of this study showed a more expressive improvement in efficacy evaluations among subjects treated with the combination of nucleotides + vitamin B(12), with a statistically significant superiority of the combination in pain reduction (evidenced by VAS scores). There were adverse events in both treatment groups, but these were transitory and no severe adverse event was recorded during the study period. Safety parameters were maintained throughout the study in both treatment groups. CONCLUSION: The combination of uridine, cytidine, and vitamin B(12) was safe and effective in the treatment of neuralgias arising from neural compression associated with degenerative orthopedic alterations and trauma